PD52: Bladder Cancer: Invasive V

5/5/2019

1:00 PM - 3:00 PM

Location: MCP: W184d

Abstract Presenter(s)

Maria Becerra, MD

University of Miami Miller School of Medicine
LB

Luca Boeri
Christina Darwish, BS

George Washington University School of Medicine and Health Sciences
SD

Shawn Dason, MD

Memorial Sloan Kettering Cancer Center

Slides
EG

Elizabeth Green, MD

Vanderbilt University Medical Center
DJ

Daniel Joyce
HK

Hristos Kaimakliotis, MD

Slides
DK

Deborah Kaye

Slides
Brian Langford, MD

University of Arkansas for Medical Sciences
AM

Alberto Martini, MD

Icahn School of Medicine at Mount Sinai
JM

Justin Matulay, MD

Columbia University Irving Medical Center
Tahlita Zuiverloon, MD,PHD

Erasmus MC Cancer Institute

Presentations:

1:00 PM - 1:10 PM
The Natural History of Untreated Muscle Invasive Bladder Cancer
Alberto Martini, MD
1:10 PM - 1:20 PM
FGFR3 mutations and their Relation to FGFR3 expression and Clinical Outcome in a large Radical Cystectomy Cohort: Implications for anti-FGFR3 Bladder Cancer Treatment?
Tahlita C.M. Zuiverloon, MD,PhD
1:20 PM - 1:30 PM
A multicenter Phase 1b/2 study of neoadjuvant pembrolizumab and cisplatin chemotherapy for muscle invasive urothelial cancer
Hristos Kaimakliotis
1:30 PM - 1:40 PM
The Impact of Neoadjuvant Chemotherapy for Squamous Histology in Patients with Muscle Invasive Bladder Cancer
Justin T. Matulay, MD
1:40 PM - 1:50 PM
Trends in Treatment and Comparison of Outcomes in Lymph Node Positive Bladder Cancer
Christina Darwish, BS – George Washington University School of Medicine
1:50 PM - 2:00 PM
Clinical predictors and survival outcome of patient receiving suboptimal neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: a single-center experience
Luca Boeri
2:00 PM - 2:10 PM
The feasibility, safety and impact of a prehabilitation program for patients undergoing cystectomy
Deborah R. Kaye
2:10 PM - 2:20 PM
PRE-OPERATIVE NARCOTIC USE IS ASSOCIATED WITH INCREASING LENGTH OF STAY AND POST-OPERATIVE COMPLICATIONS IN PATIENTS UNDERGOING RADICAL CYSTECTOMY
Elizabeth A. Green, MD
2:20 PM - 2:30 PM
Late recurrences following radical cystectomy have distinct prognostic and management considerations
Shawn Dason, MD
2:30 PM - 2:40 PM
Early Postoperative Morbidity of Robotic Versus Open Radical Cystectomy in the Obese Patient with Bladder Cancer: Report from National Surgical Quality Improvement Program Database
Brian T. Langford, MD
2:40 PM - 2:50 PM
Health related Quality of Life Outcomes by Urinary Diversion: An analysis from the randomized robotic versus open radical cystectomy (RAZOR) trial
Maria F. Becerra, MD
2:50 PM - 3:00 PM
PREDICTORS OF COMPLIANCE WITH MUSCLE INVASIVE BLADDER CANCER QUALITY MEASURES AND ITS EFFECT ON SURVIVAL OUTCOMES
Daniel D. Joyce